Cost-effectiveness of a medication event monitoring system for tuberculosis management in Morocco.
<h4>Background</h4>Digital health technologies have been used to enhance adherence to TB medication, but the cost-effectiveness remains unclear.<h4>Methods</h4>We used the real data from the study conducted from April 2014 to December 2020 in Morocco using a smart pillbox wit...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0267292&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <h4>Background</h4>Digital health technologies have been used to enhance adherence to TB medication, but the cost-effectiveness remains unclear.<h4>Methods</h4>We used the real data from the study conducted from April 2014 to December 2020 in Morocco using a smart pillbox with a web-based medication monitoring system, called Medication Event Monitoring Systems (MEMS). Cost-effectiveness was evaluated using a decision analysis model including Markov model for Multi-drug resistant (MDR) TB from the health system perspective. The primary outcome was the incremental cost-effectiveness ratio (ICER) per disability adjusted life-year (DALY) averted. Two-way sensitive analysis was done for the treatment success rate between MEMS and standard of care.<h4>Results</h4>The average total per-patient health system costs for treating a new TB patient under MEMS versus standard of care were $398.70 and $155.70, respectively. The MEMS strategy would reduce the number of drug-susceptible TB cases by 0.17 and MDR-TB cases by 0.01 per patient over five years. The ICER of MEMS was $434/DALY averted relative to standard of care, and was most susceptible to the TB treatment success rate of both strategies followed by the managing cost of MEMS.<h4>Conclusion</h4>MEMS is considered cost-effective for managing infectious active TB in Morocco. |
|---|---|
| ISSN: | 1932-6203 |